Xlife Sciences AG Market Cap ($63.73 Million)
Market Cap & Net Worth: Xlife Sciences AG (XLS)
Xlife Sciences AG market cap. Xlife Sciences AG (SW:XLS) has a market capitalization of $63.73 Million (CHF50.41 Million) as of November 5, 2026. Listed on the SW stock exchange, this Switzerland-based company holds position #20790 globally and #197 in its home market, demonstrating a -7.42% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Xlife Sciences AG's stock price CHF8.74 by its total outstanding shares 5767572 (5.77 Million). Also see XLS operating cash flow for how efficiently the company converts equity into cash flow.
Xlife Sciences AG Market Cap History (2022–2026)
Xlife Sciences AG market cap history from 2022 to 2026. Data shows change from $216.57 Million to $63.73 Million (-31.40% CAGR). Check XLS stock price for real-time trading data and today's change.
Xlife Sciences AG Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Xlife Sciences AG's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore XLS net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
654.19x
Xlife Sciences AG's market cap is 654.19 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $216.57 Million | $1.03 Million | $14.31 Million | 210.67x | 15.13x |
| 2023 | $363.86 Million | $988.44K | $14.88 Million | 368.11x | 24.45x |
| 2024 | $185.21 Million | $834.88K | $34.28 Million | 221.84x | 5.40x |
| 2025 | $180.11 Million | $275.31K | -$21.55 Million | 654.19x | N/A |
Competitor Companies of XLS by Market Capitalization
Companies near Xlife Sciences AG in the global market cap rankings as of November 5, 2026. Also see Xlife Sciences AG asset portfolio for a full breakdown of the balance sheet.
Key companies related to Xlife Sciences AG by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of Xlife Sciences AG (2022–2026)
Market capitalization of Xlife Sciences AG from 2022 to today. Between 2022 and today, Xlife Sciences AG's market cap moved from $216.57 Million to $ 63.73 Million, with a yearly change of -31.40%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CHF63.73 Million | -64.62% |
| 2025 | CHF180.11 Million | -2.76% |
| 2024 | CHF185.21 Million | -49.10% |
| 2023 | CHF363.86 Million | +68.01% |
| 2022 | CHF216.57 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Xlife Sciences AG was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $63.73 Million USD |
| MoneyControl | $63.73 Million USD |
| MarketWatch | $63.73 Million USD |
| marketcap.company | $63.73 Million USD |
| Reuters | $63.73 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Xlife Sciences AG
Xlife Sciences AG focuses on the development and commercialization of research projects in the life sciences sector. The company's project covers technology platforms, biotechnology/therapies, medical technology, and artificial intelligence/digital health areas that focuses on identifying new therapeutic approaches and biomarkers for common diseases based on human genetic data; and offers clinica… Read more